Core Laboratories Inc. /DE/ (CLB) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-13

Key Insights

All three shareholder proposals were approved at the Annual Meeting, including re-election of two Class I directors, ratification of KPMG as auditor, and advisory approval of executive compensation, indicating general shareholder support for company leadership and governance.
Harvey Klingensmith received significantly higher withheld votes (3.76M) compared to Curtis Anastasio (0.36M) despite both being elected, suggesting potential shareholder concerns about Klingensmith's performance or compensation that warrant monitoring.
Strong ratification of KPMG as independent auditor (98.9% approval) and executive compensation approval (96.8% support) demonstrate shareholder confidence in the company's financial controls and management structure.

Want the newest filings?

This analysis covers the filing from 2026-05-13. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-29

Core Laboratories announced Q1 2026 financial results on April 29, 2026, with the full results disclosed in the press release but not detailed in this 8-K filing itself.
The company declared a nominal quarterly cash dividend of $0.01 per share, indicating maintenance of shareholder returns despite the small payout amount suggesting either capital constraints or a recent dividend restructuring.
This is a routine quarterly earnings announcement with no material events, strategic changes, or significant operational updates reported in the filing.

Filed: 2026-03-23

Core Laboratories Inc. has revised its previously issued earnings guidance for the first quarter of 2026, indicating a potential surprise for investors.
The filing does not provide details on the reasons behind the guidance revision, which could suggest either positive or negative factors impacting the company's performance.
Investors should closely monitor any subsequent announcements or reports from the company to understand the full context and implications of this guidance update.

Filed: 2026-03-05

Core Laboratories Inc. has amended its bylaws to lower the voting threshold for approval of certain shareholder actions, including merger and change in control transactions, from a 66-2/3% supermajority vote to a 50% plus one simple majority vote. This change could make it easier for potential acquirers to gain control of the company.
The amended bylaws are the only change made to the company's governing documents, indicating that there are no other significant governance changes at this time.
Investors should monitor any future changes to the company's bylaws or other governing documents, as they can have important implications for shareholder rights and the balance of power between management and shareholders.

Filed: 2026-02-04

Core Laboratories Inc. announced its Q4 2025 and full year 2025 financial results, providing investors with an update on the company's recent performance.
The company declared a quarterly cash dividend of $0.01 per share of common stock, indicating a continued commitment to returning capital to shareholders.
The filing does not indicate any significant events or changes that would be considered material to investors, suggesting a relatively stable quarter for the company.

Other reports for Core Laboratories Inc. /DE/

Insider Trading Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.